Immunogenic and efficacious SARS-CoV-2 vaccine based on resistin-trimerized spike antigen SmT1 and SLA archaeosome adjuvant

AbstractThe huge worldwide demand for vaccines targeting SARS-CoV-2 has necessitated the continued development of novel improved formulations capable of reducing the burden of the COVID-19 pandemic. Herein, we evaluated novel protein subunit vaccine formulations containing a resistin-trimerized spike antigen, SmT1. When combined with sulfated lactosyl archaeol (SLA) archaeosome adjuvant, formulations induced robust antigen-specific humoral and cellular immune responses in mice. Antibodies had strong neutralizing activity, preventing viral spike binding and viral infection. In addition, the formulations were highly efficacious in a hamster challenge model reducing viral load and body weight loss even after a single vaccination. The antigen-specific antibodies generated by our vaccine formulations had stronger neutralizing activity than human convalescent plasma, neutralizing the spike proteins of the B.1.1.7 and B.1.351 variants of concern. As such, our SmT1 antigen along with SLA archaeosome adjuvant comprise a promising platform for the development of efficacious protein subunit vaccine formulations for SARS-CoV-2.

Download Full-text

Development of a new type of influenza subunit vaccine made by muramyldipeptide-liposome: enhancement of humoral and cellular immune responses

Vaccine ◽

10.1016/0264-410x(90)90254-j ◽

1990 ◽

Vol 8 (5) ◽

pp. 503-509 ◽

Cited By ~ 43

Author(s):

Kuniaki Nerome ◽

Yasuyuki Yoshioka ◽

Masatoshi Ishida ◽

Kunio Okuma ◽

Tetsuya Oka ◽

...

Keyword(s):

Immune Responses ◽

Subunit Vaccine ◽

Cellular Immune Responses ◽

New Type ◽

Cellular Immune

Download Full-text

Immunity to SARS-CoV-2 in a Dialyzed Patient Who Developed COVID-19 Twenty Days After the Second Dose of BNT162b2 Vaccine: a Case Report

10.21203/rs.3.rs-711429/v1 ◽

2021 ◽

Author(s):

Sabrina MANNI ◽

Laurène LOTTE ◽

Antonin BAL ◽

Laurence JOSSET ◽

Bruno LINA ◽

...

Keyword(s):

Risk Factors ◽

Immune Responses ◽

Cellular Response ◽

Vaccine Dose ◽

Severe Pneumonia ◽

Whole Genome ◽

Serum Specimen ◽

Neutralizing Activity ◽

Cellular Immune Responses ◽

Cellular Immune

Abstract IntroductionEnd stage kidney disease (ESKD) and cancer have been identified as risk factors for severe and fatal cases of COVID-19, making vaccination in these patients a priority. Patients suffering from ESKD have a significantly weaker response to common vaccines than general population. However, humoral and cellular immune responses after two doses of RNA-based vaccine BNT162b2 (Pfizer–BioNTech) have been poorly explored in this vulnerable population.Case presentationA 69-year-old male patient was followed for ESKD and myeloma. He developed a severe SARS-CoV-2 pneumonia twenty days after two doses of BNT162b2 vaccine. Whole genome sequencing found that the virus belonged to the 20I/501Y.V1 clade. A serology draws eight days after the 2nd vaccine dose showed positive RBD IgG without neutralizing activity. A serum specimen sampled thirty days after the onset of SARS-CoV-2 infection showed seroconversion against both RBD and N antigens. This specimen was shown to exhibit a frank neutralizing activity. The QuantiFERON® SARS-CoV-2 (Qiagen) showed a positive specific cellular response although the QuantiFERON monitor displayed a weak cellular response. ConclusionsImpaired immunity due to renal failure probably explain the severe pneumonia despite vaccination. The fact that the patient developpe a neutralizing activity and a cellular response after a third stimulation by infection may suggest to systemically administrate a third dose of vaccine in ESKD patients.

Download Full-text

Sustained maternal antibody and cellular immune responses in pregnant women infected with Zika virus and mother to infant transfer of Zika‐specific antibodies

American Journal of Reproductive Immunology ◽

10.1111/aji.13288 ◽

2020 ◽

Vol 84 (4) ◽

Author(s):

Ai‐ris Y. Collier ◽

Erica N. Borducchi ◽

Abishek Chandrashekar ◽

Edward Moseley ◽

Lauren Peter ◽

...

Keyword(s):

Immune Responses ◽

Pregnant Women ◽

Zika Virus ◽

Maternal Antibody ◽

Specific Antibodies ◽

Cellular Immune Responses ◽

Cellular Immune ◽

Infant Transfer

Download Full-text

Comparison of the humoral and cellular immune responses after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations

Archives of Virology ◽

10.1007/bf01317862 ◽

1976 ◽

Vol 52 (1-2) ◽

pp. 29-35 ◽

Cited By ~ 28

Author(s):

R. Cappel

Keyword(s):

Herpes Simplex Virus ◽

Herpes Simplex ◽

Immune Responses ◽

Subunit Vaccine ◽

Cellular Immune Responses ◽

A Subunit ◽

Simplex Virus ◽

Cellular Immune

Download Full-text

Humoral and cellular immune responses in sheep immunized with a 22 kilodalton exported protein of Mycobacterium avium subspecies paratuberculosis

Journal of Medical Microbiology ◽

10.1099/jmm.0.46785-0 ◽

2006 ◽

Vol 55 (12) ◽

pp. 1735-1740 ◽

Cited By ~ 14

Author(s):

Rachael C. Rigden ◽

Dakshina M. Jandhyala ◽

Chris Dupont ◽

Dianna Crosbie-Caird ◽

Nicolas Lopez-Villalobos ◽

...

Keyword(s):

Immune Responses ◽

Mycobacterium Avium ◽

Mycobacterium Avium Subspecies Paratuberculosis ◽

Specific Antibodies ◽

Antibody Recognition ◽

Cellular Immune Responses ◽

Exported Protein ◽

Cellular Immune

An immunogenic 22 kilodalton exported Mycobacterium avium subspecies paratuberculosis (MAP) lipoprotein (P22) was previously identified, and found to belong to the LppX/LprAFG family of mycobacterial lipoproteins. N-terminal polyhistidine-tagged P22 was produced and purified from Escherichia coli. Antibody recognition of P22, and interferon-gamma (IFN-γ) responses in vitro using blood from a sheep vaccinated with Neoparasec, confirmed its immunogenicity. To evaluate the immunogenicity of P22 in vivo, five sheep were immunized with a single dose containing 0.8 mg recombinant P22 protein in adjuvant. Blood was collected at 4, 13 and 29 weeks post-immunization (p.i.) and tested for anti-P22 antibodies and P22-specific IFN-γ production. P22-specific antibodies were detected by Western blot analysis in all five Neoparasec-immunized sheep at the three time points. Three out of five P22-immunized sheep produced P22-specific antibodies for up to 13 weeks p.i., and two gave a response at 29 weeks p.i. Recombinant P22 was able to stimulate significant IFN-γ production in blood of P22-immunized sheep at 13 and 29 weeks p.i. Recombinant P22 also elicited an IFN-γ response in blood of sheep immunized with Neoparasec.

Download Full-text

Neutralizing activity and cellular immune responses induced in mice after immunization with apoptotic HIV-1/murine leukemia virus infected cells

Vaccine ◽

10.1016/j.vaccine.2009.06.016 ◽

2009 ◽

Vol 27 (46) ◽

pp. 6424-6431 ◽

Cited By ~ 4

Author(s):

Jorma Hinkula ◽

Lilian Walther-Jallow ◽

Anna Laurén ◽

Barbro Mäkitalo ◽

Monica Öberg ◽

...

Keyword(s):

Immune Responses ◽

Murine Leukemia Virus ◽

Leukemia Virus ◽

Neutralizing Activity ◽

Cellular Immune Responses ◽

Infected Cells ◽

Cellular Immune ◽

Hiv 1 ◽

Murine Leukemia

Download Full-text

BoHV-1-Vectored BVDV-2 Subunit Vaccine Induces BVDV Cross-Reactive Cellular Immune Responses and Protects against BVDV-2 Challenge

Vaccines ◽

10.3390/vaccines9010046 ◽

2021 ◽

Vol 9 (1) ◽

pp. 46

Author(s):

Shafiqul I. Chowdhury ◽

Katrin Pannhorst ◽

Neha Sangewar ◽

Selvaraj Pavulraj ◽

Xue Wen ◽

...

Keyword(s):

Immune Responses ◽

Subunit Vaccine ◽

Protective Efficacy ◽

Neutralizing Antibody ◽

Herpesvirus Type ◽

Safety Issues ◽

Diarrhea Virus ◽

Gm Csf ◽

Cellular Immune Responses ◽

Cellular Immune

The bovine respiratory disease complex (BRDC) remains a major problem for both beef and dairy cattle industries worldwide. BRDC frequently involves an initial viral respiratory infection resulting in immunosuppression, which creates a favorable condition for fatal secondary bacterial infection. Current polyvalent modified live vaccines against bovine herpesvirus type 1(BoHV-1) and bovine viral diarrhea virus (BVDV) have limitations concerning their safety and efficacy. To address these shortcomings and safety issues, we have constructed a quadruple gene mutated BoHV-1 vaccine vector (BoHV-1 QMV), which expresses BVDV type 2, chimeric E2 and Flag-tagged Erns-fused with bovine granulocyte monocyte colony-stimulating factor (GM-CSF) designated here as QMV-BVD2*. Here we compared the safety, immunogenicity, and protective efficacy of QMV-BVD2* vaccination in calves against BVDV-2 with Zoetis Bovi-shield Gold 3 trivalent (BoHV-1, BVDV types 1 and 2) vaccine. The QMV-BVD2* prototype subunit vaccine induced the BoHV-1 and BVDV-2 neutralizing antibody responses along with BVDV-1 and -2 cross-reactive cellular immune responses. Moreover, after a virulent BVDV-2 challenge, the QMV-BVD2* prototype subunit vaccine conferred a more rapid recall BVDV-2-specific neutralizing antibody response and considerably better recall BVDV types 1 and 2-cross protective cellular immune responses than that of the Zoetis Bovi-shield Gold 3.

Download Full-text